


EVALUATE-HF

#ESCCongress



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with heart failure with reduced ejection fraction were randomized to sacubitril/valsartan (97/103 mg twice daily) versus enalapril (10 mg twice daily) for 12 weeks.



RESULTS

- Primary endpoint: change in aortic impedance from baseline to 12 weeks was -2.9 in the sacubitril/valsartan group compared with -0.7 in the enalapril group (p = 0.78)
- Adverse events, including hypotension: 1.7% in the sacubitril/valsartan group vs. 3.9% in the enalapril group (p = 0.001)

CONCLUSIONS

- Among patients with heart failure with reduced ejection fraction, sacubitril/valsartan vs. enalapril did not reduce central aortic stiffness
- Sacubitril/valsartan was well tolerated

Desai AS, et al. JAMA 2019;Sep 2:[Epub]